Sector News

Stryker announces commercial structure realignment

August 19, 2019
Life sciences

Stryker has announced an adjustment to its commercial organizational structure. Spencer S. Stiles will serve as Group President of Orthopaedics and Spine and will oversee Stryker’s Joint Replacement, Trauma & Extremities and Spine divisions. J. Andrew Pierce, Group President of MedSurg and Neurotechnology will oversee Stryker’s Instruments, Medical, Endoscopy, Sustainability and Neurotechnology businesses.

Mr. Stiles and Mr. Pierce have both served at Stryker for over 20 years and will continue to report to Timothy J. Scannell, President and Chief Operating Officer in their newly expanded roles. Since August of 2018, Mr. Scannell has been responsible for all of the company’s commercial businesses and regions. This change will further accelerate the globalization and collaboration opportunities being unlocked in this structure and leverage the diverse experience of these leaders.

Stuart F. Simpson, President of Joint Replacement has left the company to pursue other career interests.

Source: Stryker

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach